The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Where Do Diabetologists Stand?
Clin Diabetes Endocrinol. 2020 Jun 5;6:9. doi: 10.1186/s40842-020-00097-1.eCollection 2020.
Shaheen Tomah12, Naim Alkhouri3, Osama Hamdy12
Author information
1Research Division, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215 USA.
2Department of Medicine, Harvard Medical School, Boston, MA 02215 USA.
3Texas Liver Institute, University of Texas (UT) Health, San Antonio, TX USA.
Free PMC article
Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. The increasing prevalence of NAFLD mirrors that of obesity and type 2 diabetes over the last two decades.
Main: In a two-way pathophysiologic relationship, NAFLD increases the risk of developing type 2 diabetes, while the latter promotes the progression of simple fatty liver to a more advanced form called nonalcoholic steatohepatitis (NASH). NASH increases the risk of cirrhosis and hepatocellular carcinoma (HCC), which may require liver transplantation. With the absence of FDA-approved medications for NAFLD treatment, lifestyle intervention remains the only therapy. Lately, extensive research efforts have been aimed at modifying NASH fibrosis and developing noninvasive screening methods.
Conclusion: We highlight the pathophysiologic relationships between NAFLD and type 2 diabetes, discuss disease recognition, models of care, and current and emerging therapies for NASH treatment.